Literature DB >> 34643432

M1 Macrophage Polarization Prevails in Epstein-Barr Virus-Infected Children in an Immunoregulatory Environment.

A Moyano1, N M Ferressini Gerpe1, E De Matteo2, M V Preciado1, P Chabay1.   

Abstract

Macrophages can be polarized toward a proinflammatory phenotype (M1) (CD68+) or to an anti-inflammatory one (M2) (CD163+). Polarization can be triggered by cytokines such as IFN-γ for M1, or IL-10 and TGF-β, for M2. In the context of pediatric Epstein Barr virus (EBV) infection, little is known about macrophage polarization in EBV primary or persistent infection. When studying tonsils of patients undergoing primary infection (PI), healthy carrier (HC), reactivation (R), and not infected (NI), M1 profile prevailed in all infection status. However, an increase in M2 cells was observed in those patients with broader expression of latency antigens, in particular EBNA2. Tonsils from primary infected patients showed an increased IL-10 expression, whereas, unexpectedly, TGF-β expression correlated with M1 marker. Furthermore, an inverse correlation was demonstrated between CD68 and IFN-γ. Therefore, in the context of asymptomatic infection in children, M1 macrophage polarization prevails, even in the presence of IL-10 and TGF-Ꞵ immunomodulatory cytokines, and it might be independent from lymphomagenesis process. Our finding indicates that macrophages may have a significant plasticity in response to different types of extrinsic stimuli, and further studies are required to investigate M1 polarization under anti-inflammatory stimuli. IMPORTANCE Most studies on Epstein Barr virus (EBV) primary infection have been performed in adolescents and young adult populations with Infectious Mononucleosis (IM) in developed countries. Furthermore, studies related to macrophage polarization were assessed in EBV-associated lymphomas, but little is known about macrophage polarization in the context of primary infection at the site of viral entry and replication, the tonsils. Therefore, the aim of this study was to characterize macrophage response in children undergoing EBV primary or persistent infection, in order to enlighten the role of macrophages in viral pathogenesis, in a population with a high incidence of EBV-associated lymphomas in children younger than 10 years old. This study may contribute to explain, at least in part, the asymptomatic viral infection in children from an underdeveloped region, given that M1 polarization pattern prevails, but in a regulatory environment.

Entities:  

Keywords:  Epstein Barr virus; children; macrophages; polarization

Mesh:

Substances:

Year:  2021        PMID: 34643432      PMCID: PMC8754231          DOI: 10.1128/JVI.01434-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   6.549


  43 in total

1.  Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus.

Authors:  Nadine Honke; Namir Shaabani; Giuseppe Cadeddu; Ursula R Sorg; Dong-Er Zhang; Mirko Trilling; Karin Klingel; Martina Sauter; Reinhard Kandolf; Nicole Gailus; Nico van Rooijen; Christoph Burkart; Stephan E Baldus; Melanie Grusdat; Max Löhning; Hartmut Hengel; Klaus Pfeffer; Masato Tanaka; Dieter Häussinger; Mike Recher; Philipp A Lang; Karl S Lang
Journal:  Nat Immunol       Date:  2011-11-20       Impact factor: 25.606

2.  Tumor-associated macrophages in pediatric classical Hodgkin lymphoma: association with Epstein-Barr virus, lymphocyte subsets, and prognostic impact.

Authors:  Mário Henrique M Barros; Rocio Hassan; Gerald Niedobitek
Journal:  Clin Cancer Res       Date:  2012-05-29       Impact factor: 12.531

3.  Distribution and phenotype of Epstein-Barr virus-infected cells in human pharyngeal tonsils.

Authors:  S David Hudnall; Yimin Ge; Longxing Wei; Ning-Ping Yang; Hui-Quin Wang; Tiansheng Chen
Journal:  Mod Pathol       Date:  2005-04       Impact factor: 7.842

4.  The interplay between local immune response and Epstein-Barr virus-infected tonsillar cells could lead to viral infection control.

Authors:  Aldana G Vistarop; Melina Cohen; Fuad Huaman; Lucia Irazu; Marcelo Rodriguez; Elena De Matteo; María Victoria Preciado; Paola A Chabay
Journal:  Med Microbiol Immunol       Date:  2018-07-25       Impact factor: 3.402

5.  Germinal center B cells latently infected with Epstein-Barr virus proliferate extensively but do not increase in number.

Authors:  Jill E Roughan; Charles Torgbor; David A Thorley-Lawson
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

6.  B cell maintenance of subcapsular sinus macrophages protects against a fatal viral infection independent of adaptive immunity.

Authors:  E Ashley Moseman; Matteo Iannacone; Lidia Bosurgi; Elena Tonti; Nicolas Chevrier; Alexei Tumanov; Yang-Xin Fu; Nir Hacohen; Ulrich H von Andrian
Journal:  Immunity       Date:  2012-03-01       Impact factor: 31.745

7.  Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.

Authors:  María Dolores Fellner; Karina A Durand; Veronica Solernou; Andrea Bosaleh; Ziomara Balbarrey; María T García de Dávila; Marcelo Rodríguez; Lucía Irazu; Lidia V Alonio; María A Picconi
Journal:  Rev Argent Microbiol       Date:  2016-05-04       Impact factor: 1.852

8.  Epstein-Barr virus Zta-induced immunomodulators from nasopharyngeal carcinoma cells upregulate interleukin-10 production from monocytes.

Authors:  Chien-Hsun Lee; Tzu-Hao Yeh; Hsiao-Ching Lai; Shih-Yi Wu; Ih-Jen Su; Kenzo Takada; Yao Chang
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

Review 9.  Role of Human Macrophage Polarization in Inflammation during Infectious Diseases.

Authors:  Chiraz Atri; Fatma Z Guerfali; Dhafer Laouini
Journal:  Int J Mol Sci       Date:  2018-06-19       Impact factor: 5.923

10.  Revisiting the Tissue Microenvironment of Infectious Mononucleosis: Identification of EBV Infection in T Cells and Deep Characterization of Immune Profiles.

Authors:  Mário Henrique M Barros; Gabriela Vera-Lozada; Priscilla Segges; Rocio Hassan; Gerald Niedobitek
Journal:  Front Immunol       Date:  2019-02-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.